Discover
The Dime
The Dime
Author: Bryan Fields
Subscribed: 16Played: 349Subscribe
Share
© 2026 The Dime
Description
Most cannabis companies won't survive the next three years. The ones that do will have better capital discipline, sharper regulatory reads, and operational frameworks built for compression, not growth. The Dime is where cannabis operators, executives, and investors hear directly from the CEOs and founders making those decisions right now: MSO strategy, state-by-state market dynamics, cultivation and extraction economics, brand positioning, and the financing structures keeping companies alive. Bryan Fields hosts weekly conversations built for operators, not observers.
309 Episodes
Reverse
Throughput is the easiest extraction metric to celebrate and one of the easiest ways to hide a losing system.An operator can move more biomass while sacrificing recovery, product quality, margin, and the ability to respond when demand shifts. Matt Erickson argues that extraction should be designed around the business outcome, then separated into repeatable ingredient and formulation workflows that make costs, handoffs, and constraints visible.This week we sit down with Matt EricksonProfit before raw speedTHCA and HTE workflowsProving equipment claimsAlternate opening hook: A faster extraction line can make the scoreboard look better while the business gets worse.Chapters00:00 Throughput vs Performance02:49 Profitability as the North Star07:39 Standardizing Across MSOs08:20 Customize Equipment Standardize Process12:25 Tribal Knowledge and Scalability18:04 The Leaky Bucket19:07 Dirty Data Inside the Lab21:13 The Cost of Chasing Efficiency22:40 Ingredient Based Manufacturing24:17 THCA and HTE28:51 Separating Extraction From Formulation30:03 Formulating With Demand32:52 Assembly Line Specialization34:44 Verification and Pharmaceutical Logic36:09 Shortening the Feedback Loop37:02 Why Generic SOPs Fail38:15 Upgrade or Rebuild40:59 The Cookie Cutter Equipment Problem42:16 Sunk Costs and Phased Upgrades44:34 Proving the ROI47:42 The Root Cause Before the QuoteGuest LinksEvolved Extraction websiteMatthew Erickson on LinkedInMatthew Erickson on InstagramOur LinksThe Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramNewton Insights — insights for extraction teams Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The expensive decision rarely looks intelligent before the market needs it.Operators can build for the regulations in front of them, or for the direction regulators are already moving. Across global medical cannabis markets, internal labs, stability programs, EU GMP manufacturing, and control of distribution are beginning to separate companies that can scale profitably from those that can only trade product.This week we sit down with Michael SassanoEurope's 51st statePharmaceutical disciplineEBITDA before volumeChapters00:00 Schedule III and Europe02:15 Europe as the 51st state07:44 Building for pharmaceutical lead times11:44 What EU GMP changes16:14 Creativity inside the rulebook19:40 Why pharma owns the lab22:50 The economics of internal validation26:34 Could the United States adopt this model28:34 The EU GMP supply shortage32:32 Regulators close the conversion loophole35:23 Distribution consolidation begins39:46 The missing vertical43:25 A country by country strategy46:37 What SOMAI will not do49:42 Why extracts start with full bud51:38 The rules become the moat53:15 Europe as a totality of growth55:21 Where to find MichaelGuest LinksSOMAÍ Pharmaceuticals websiteMichael Sassano / SOMAÍ on XSOMAÍ on InstagramSOMAÍ on LinkedInSOMAÍ on FacebookOur LinksThe Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramNewton Insights — insights for extraction teams Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
A 115-year farm discovered that preserving the legacy meant letting a new crop compete with it.Ayrloom reached Beak & Skiff's revenue scale in three years, then forced the family to reallocate capital, people, land, and drying space while cannabis regulation kept the businesses legally separate.The advantage was not cannabis expertise. It was years of beverage manufacturing scars, retail-grade quality systems, and relationships strong enough to survive a crowded New York shelf.This week we sit down with Eddie BrennanCapital behind rapid growthQuality before repeat purchaseDefending premium through compressionChapters00:00 Sharing one farm across two companies02:18 Cannabis versus apples for space04:24 Three-year growth catches a 115-year business07:33 Growth, cash, and what breaks09:52 Why cannabis expertise is overrated12:09 Beverage scars become an operating advantage15:17 Grocery-grade quality control19:10 Consistency wins repeat purchase21:04 Making cannabis approachable23:43 The reverse gateway claim25:29 Where cannabis beverages belong27:22 Regulation and high-dose drinks30:14 Why Ayrloom stays narrow and deep34:22 Price compression and retail health37:05 When an in-house brand outruns co-manufacturing39:39 What changes in a new market42:10 The pressure of a fifth-generation legacy44:35 Where to find AyrloomGuest LinksEddie Brennan - ayrloomOur LinksThe Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramNewton Insights — insights for extraction teamsFollow The Dime for more conversations on cannabis business, operations, and international markets.Share this episode with an operator rethinking their edibles. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise.The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge.This week we sit down with Jay RosenthalLimbo as a moatEU GMP advantageRegulation's hidden winnersChapters00:00 Federal limbo becomes the business model02:17 The reform everyone agrees on03:28 Capital markets and the bigger pond05:35 Six hundred brands and no patience06:55 Why Rochester can move New York09:48 Strong operators become obvious13:40 The cost of crossing state lines16:28 Aurora Curaleaf and scarce EU GMP assets20:26 The Canadian future that did not arrive22:00 What mature industry compliance could bring24:35 Cultivated's nonsecret sauce31:41 Cannabis stigma still follows the operator32:28 Why Cultivated launched membership40:23 Quality media has a real cost41:18 California and New York regulators share a market44:02 Policy goals that fight each other49:06 Competition cooperation and price compression52:25 Where to find Jay and CultivatedGuest LinksJay Rosenthal - Co-Founder and Managing Director of Cultivated MediaCultivated MediaCultivated eventsSign up for the Cultivated Daily newsletterOur LinksThe Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramNewton Insights — insights for extraction teamsFollow The Dime for more conversations on cannabis business, operations, and international markets.Share this episode with an operator rethinking their edibles. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time.This week we sit down with Kim Sanchez RaelFast onset economicsThe nano problemScience/ AI and so much moreFast-acting cannabis edibles promise a more predictable experience, but the language on the package does not always tell operators what happens in the final product.Kim Sanchez Rael, President and CEO of Azuca, breaks down what "fast" should mean, why slow-onset edibles still dominate, and how formulation choices affect taste, stability, curing time, shelf life, and production efficiency. She explains why "nano" is often a measurement or marketing label rather than proof of a better consumer outcome, then offers four questions brands should ask any infusion supplier.The conversation also moves beyond formulation. Kim describes the economics behind fast-acting products, the role of supplier behavior when production is at risk, the case for a single regulatory framework for the cannabis plant, and why operators cannot build a business that depends on an unpredictable regulatory change.Topics include:The consumer value of predictable onsetManufacturing tradeoffs in gummy formulationWhat brands should demand from infusion partnersWhy structured quality systems matterHow Azuca uses AI inside its team and customer experienceLearn more about Azuca and TiME INFUSION® at https://azuca.co/.Guest: Kim Sanchez Rael, President and CEO, AzucaHost: Bryan Fields, The DimeChapters00:01 Why slow-onset edibles still dominate01:47 The economics of fast acting03:56 Can brands claim "fast"?05:56 Predictability and consumer trust08:06 The retail education gap10:24 How Azuca licensing works14:44 Formulation, cannabinoids, and flavor15:30 When "fast" does not feel fast18:18 Onset, peak, and duration20:01 Manufacturing efficiency R&D23:14 Validating infusion science24:43 Why "nano" is a buzzword27:38 The operational cost of change28:24 Four questions for infusion suppliers30:00 Supplier behavior as brand experience32:31 The Fourth of July production rescue33:48 What cannabis still gets wrong34:15 The One Plant Solution37:04 Policy resistance and incrementalism38:41 AI and "Kimothy"41:21 Quality systems and sustainable math44:58 The question Kim wishes people asked45:45 Where to find AzucaOur LinksThe Dime Podcast — websiteBryan Fields on XThe Dime on XThe Dime on YouTubeThe Dime on InstagramEighth RevolutionNewton Insights — insights for extraction teamsFollow The Dime for more conversations on cannabis business, operations, and international markets.Share this episode with an operator rethinking their edibles.Guest LinksKim Sanchez Rael — Azuca Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.



